These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 11401659)

  • 1. A prospective study of 86 new patients with social anxiety disorder.
    Allgulander C; Nilsson B
    Acta Psychiatr Scand; 2001 Jun; 103(6):447-52. PubMed ID: 11401659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.
    Baldwin D; Bobes J; Stein DJ; Scharwächter I; Faure M
    Br J Psychiatry; 1999 Aug; 175():120-6. PubMed ID: 10627793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
    Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
    Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: initial validation of an imaging protocol for drug discovery.
    Giménez M; Ortiz H; Soriano-Mas C; López-Solà M; Farré M; Deus J; Martín-Santos R; Fernandes S; Fina P; Bani M; Zancan S; Pujol J; Merlo-Pich E
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):105-16. PubMed ID: 24332890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
    Zourková A; Hadasová E
    Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in recognition and treatment of social anxiety disorder: a 10-year retrospective.
    Stein MB
    Psychopharmacol Bull; 2003; 37 Suppl 1():97-107. PubMed ID: 14566205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxetine treatment of mood and anxiety disorders in children and adolescents.
    Wagner KD
    Psychopharmacol Bull; 2003; 37 Suppl 1():167-75. PubMed ID: 14566209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity.
    Zourková A; Cesková E; Hadasová E; Ravcuková B
    J Sex Marital Ther; 2007; 33(4):343-55. PubMed ID: 17541852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol.
    Laugesen S; Enggaard TP; Pedersen RS; Sindrup SH; Brøsen K
    Clin Pharmacol Ther; 2005 Apr; 77(4):312-23. PubMed ID: 15903129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind placebo-controlled pilot study of paroxetine for specific phobia.
    Benjamin J; Ben-Zion IZ; Karbofsky E; Dannon P
    Psychopharmacology (Berl); 2000 Apr; 149(2):194-6. PubMed ID: 10805616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
    Murata Y; Kobayashi D; Imuta N; Haraguchi K; Ieiri I; Nishimura R; Koyama S; Mine K
    J Clin Psychopharmacol; 2010 Feb; 30(1):11-7. PubMed ID: 20075642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Social anxiety and propranolol abuse: a case study].
    Fontanella BJ
    Braz J Psychiatry; 2003 Oct; 25(4):228-30. PubMed ID: 15328549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics and persistence of CYP2D6 inhibition by paroxetine.
    Juřica J; Žourková A
    J Clin Pharm Ther; 2013 Aug; 38(4):294-300. PubMed ID: 23437966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.
    Stein MB; Sareen J; Hami S; Chao J
    Am J Psychiatry; 2001 Oct; 158(10):1725-7. PubMed ID: 11579011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.